Video: Transform health research by democratising clinical trials
Protas joins colleagues at Milken Institute Global Conference to discuss democratic clinical trials.
The latest in smarter trials
As a not-for-profit, our mission is to enable whole-system change in clinical trials. This means sharing our approach and knowledge with our community. From news about Protas, our partnerships and trials, to advice and guidance, discover more about our world.
Protas collaborates with GSK to advise on optimising protocol development
Protas will advise GSK on clinical trial protocols across a range of late-phase investigational products.
Video: On stage at JP Morgan Healthcare Conference
Prof Sir Martin Landray joins Salesforce and Slalom to talk about our collaboration in revolutionising clinical trials.
Smarter clinical trials for a healthier population
Prof Sir Martin Landray writes about how clinical trials are key to common disease prevention, early detection and treatment.
Tackling common disease burden through clinical trial innovation
As part of New Scientist’s 2023 campaign on innovation in clinical research and development, Prof Sir Martin Landray explores the pressing need to transform clinical…
Protas gains ISO 9001 certification for high standards of quality
The international accreditation acknowledges our approach to quality.
Meet the team: Abbie Gerard, Clinical Quality Assurance Specialist
Abbie Gerard shares what motivated her to move from academia to a new not-for-profit.
Apollo Therapeutics and Protas partner to advance therapeutic programmes
Protas will provide expertise to the portfolio biopharma on a range of drug development programmes.
Meet the board: Esther Krofah
The Executive Vice President of Milken Institute Health shares what drew her to Protas.
Meet the team: Venkatakrishnan Rajendran, Clinical Operations Manager
Venkat Rajendran shares his exciting, and sometimes unusual, career trajectory.
Meet the team: Jonathan Solomon, Legal Counsel
Jonathan Solomon shares what drew him from private practice to a clinical trial not-for-profit.
O’Shaughnessy review: Protas, Oxford and Good Clinical Trials Collaborative respond
Together, the three organisations are calling for actions not words in The Lancet.